

# VERACYTE, INC.

## **FORM 8-K** (Current report filing)

Filed 06/06/17 for the Period Ending 06/06/17

Address	6000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO, CA 94080
Telephone	(650) 243-6300
CIK	0001384101
Symbol	VCYT
SIC Code	8071 - Medical Laboratories
Industry	Biotechnology & Medical Research
Sector	Healthcare
Fiscal Year	12/31

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): June 6, 2017

**VERACYTE, INC.**

(Exact name of registrant as specified in its charter)

**DELAWARE**

(State or other jurisdiction of  
incorporation)

**001-36156**

Commission File Number

**20-5455398**

(IRS Employer Identification  
No.)

**6000 Shoreline Court, Suite 300, South San Francisco,  
California**

(Address of principal executive offices)

**94080**

(Zip Code)

Registrant's telephone number, including area code: **(650) 243-6300**

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

The following actions were taken at the Annual Meeting of Stockholders of Veracyte, Inc., held on June 6, 2017:

1. The following Class I Directors were elected to serve until the 2020 Annual Meeting of Stockholders or until their successors are duly elected and qualified:

	<b>For</b>	<b>Withheld</b>	<b>Broker Non-Votes</b>
Bonnie H. Anderson	29,748,620	487,396	1,974,587
Robert S. Epstein	28,366,435	1,869,581	1,974,587
Evan Jones	23,034,675	7,201,341	1,974,587

2. The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2017 was approved:

<b>For</b>	<b>Against</b>	<b>Abstain</b>
32,207,194	3,404	5

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 6, 2017

VERACYTE, INC.

By: /s/ Keith S. Kennedy

Name: Keith S. Kennedy

Title: *Chief Financial Officer*

*(Principal Financial and Accounting Officer)*